Efficacy and safety of domestic olmesartan in treatment of mild to moderate essential hypertension

Journal of Shanghai Jiaotong University (Medical Science)

Volumn 29, Issue 11, 2009, Pages 1359-1362

  Hu, Ya Rong ^a   Chen, Shao Xing ^a   Zhang, Jin ^a   Wang, Pei Rong ^b   Kong, Yan ^a   Zhu, Ding Hang ^a   Li, Song Hua ^c   Xu, Rong Liang ^c   Wu, Zong Gui ^d  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Shanghai Sine Promod Pharmaceutical Co Ltd   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

^d SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Antihypertensive agents; Efficacy; Losartan; Olmesartan; Safety

Indexed keywords

ANTIHYPERTENSIVE AGENT; LOSARTAN; OLMESARTAN; PLACEBO;

ADULT; ADVERSE OUTCOME; AGED; AMBULATORY MONITORING; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MONITORING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ESSENTIAL HYPERTENSION; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 77953449248     PISSN: 16748115     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Giuseppe M, Guy DB, Anna D, et al. 2007 Guidelines for management of arterial hypertension. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)[J]. J Hypertension, 2007, 25(6): 1105-1187.
2. Miura S. Do all angiotensin II type 1 receptor blockers have the same beneficial effects[J]? Br J Pharmacol, 2007, 151(7): 912-913.
3. Miura S, Fujino M, Hanzawa H, et al. Molecular mechanism underlying inverse agonist of angiotensin II type 1 receptor[J]. J Biol Chem, 2006, 281(28): 19288-19295.
4. Yoshida K, Kohzuki M. Clinical and experimental aspects of olmsartan medoxomil, a new angiotensin II receptor antagonist[J]. Cardiovasc Drug Rev, 2004, 22(4): 285-308.
5. Smith DH, Dubiel R, Jones M. Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmsartan medoxomil, losrtan potassium, valsartan, and irbesartan[J]. Am J Cardiovasc Drugs, 2005, 5(1): 41-50.
6. Chinese source
7. Chinese source
8. Chinese source
9. Destro M, Preti P, D'Ospina A, et al. Olmesaratan medoxomil: recent clinical and experimental acquistions[J]. Expert Opin Drug Metab Toxicol, 2009, 5(9): 1149-1157.